The warning, dated June 13 and received on June 17, 2025, was issued by the Deputy General Manager of SEBI. The violation pertains to non-compliance with pre-clearance requirements under the SEBI (Prohibition of Insider Trading) Regulations, 2015.
Also Read: Neuland Labs announces ₹342-crore investment to hike capacity in Telangana units
The company clarified that the issue relates to an individual and that the warning is administrative in nature. It also confirmed that there is no material impact on its financials, operations, or other business activities as a result of this matter.Fourth Quarter
Net profit for the period decreased by 59% from last year to ₹27.8 crore. Revenue for the quarter stood at ₹328 crore, which is a decline of 15% from ₹385 crore it had reported during the year-ago quarter. Neuland’s EBITDA for the quarter also fell 52% on a year-on-year basis to ₹51.1 crore, while margins contracted to 16% from 27.8% last year.
The company saw a decline in topline revenue in FY25 compared to FY24. It also reported a decline in operating margins in line with initial expectations for the year. CMS revenues stood at ₹637 crore, driven mainly by commercial-stage molecules. Despite the revenue decline, the customer base has widened.
Also Read: Neuland Laboratories shares fall 4% after equity worth ₹780 crore changes hands
Neuland Laboratories expects its growth trajectory to resume in FY26 and says it continues to have visibility on both its short- and long-term growth outlook.
Shares of Neuland Laboratories Ltd ended at ₹12,600.00, down by ₹236.85, or 1.85%, on the BSE.
